Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 796

1.

Changes in element availability induced by sterilization in heavy metal contaminated substrates: A comprehensive study.

Krauße T, Schütze E, Phieler R, Fürst D, Merten D, Büchel G, Kothe E.

J Hazard Mater. 2017 Nov 10. pii: S0304-3894(17)30830-0. doi: 10.1016/j.jhazmat.2017.11.008. [Epub ahead of print]

PMID:
29153855
2.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2017 Nov 3. doi: 10.1164/rccm.201709-1845OC. [Epub ahead of print]

PMID:
29099620
3.

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.

Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR.

J Rheumatol. 2017 Nov 1. pii: jrheum.161040. doi: 10.3899/jrheum.161040. [Epub ahead of print]

PMID:
29093152
4.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2017 Oct 25. doi: 10.1093/rheumatology/kex396. [Epub ahead of print]

PMID:
29077900
5.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJ, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2017 Oct 24. pii: annrheumdis-2017-211682. doi: 10.1136/annrheumdis-2017-211682. [Epub ahead of print]

6.

Novel synthetic vertebrae provide realistic haptics for pedicle screw placement.

Hollensteiner M, Augat P, Furst D, Esterer B, Gabauer S, Puschel K, Schrodl F, Schrempf A.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:46-49. doi: 10.1109/EMBC.2017.8036759.

PMID:
29059807
7.

A hybrid, low-cost tissue-like epidural needle insertion simulator.

Esterer B, Gabauer S, Pichler R, Wirthl D, Drack M, Hollensteiner M, Kettlgruber G, Kaltenbrunner M, Bauer S, Furst D, Merwa R, Meier J, Augat P, Schrempf A.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:42-45. doi: 10.1109/EMBC.2017.8036758.

PMID:
29059806
8.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

PMID:
28992174
9.

Assessment of skin involvement in systemic sclerosis.

Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202. Review.

PMID:
28992173
10.

Points to consider in renal involvement in systemic sclerosis.

Galluccio F, Müller-Ladner U, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201. Review.

PMID:
28992172
11.

Points to consider for skin ulcers in systemic sclerosis.

Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v67-v71. doi: 10.1093/rheumatology/kex200. Review.

PMID:
28992171
12.

Points to consider-Raynaud's phenomenon in systemic sclerosis.

Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v45-v48. doi: 10.1093/rheumatology/kex199. Review.

PMID:
28992170
13.

Points to consider when doing a trial primarily involving the heart.

Allanore Y, Distler O, Walker UA, Khanna D, Furst DE, Meune C.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v12-v16. doi: 10.1093/rheumatology/kex198. Review.

PMID:
28992169
14.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

PMID:
28992168
15.

Muscle involvement in systemic sclerosis: points to consider in clinical trials.

Walker UA, Clements PJ, Allanore Y, Distler O, Oddis CV, Khanna D, Furst DE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v38-v44. doi: 10.1093/rheumatology/kex196. Review.

PMID:
28992167
16.

Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Furst DE, Braun-Moscovic Y, Khanna D.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v4-v11. doi: 10.1093/rheumatology/kex195. Review.

PMID:
28992166
17.

Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.

Clements P, Allanore Y, Furst DE, Khanna D.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v23-v26. doi: 10.1093/rheumatology/kex194. Review.

PMID:
28992165
18.

Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis.

Khanna D, Hays RD, Furst DE.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v17-v22. doi: 10.1093/rheumatology/kex193. Review.

PMID:
28992164
19.

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE.

Scand J Rheumatol. 2017 Oct 9:1-9. doi: 10.1080/03009742.2017.1299793. [Epub ahead of print]

PMID:
28990485
20.

The Potential for Synovium-derived Stem Cells in Cartilage Repair.

Kubosch EJ, Lang GM, Fürst D, Kubosch DC, Izadpanah K, Rolauffs B, Südkamp NP, Schmal H.

Curr Stem Cell Res Ther. 2017 Oct 2. doi: 10.2174/1574888X12666171002111026. [Epub ahead of print]

PMID:
28969580

Supplemental Content

Loading ...
Support Center